NETPark-based PolyPhotonix Limited and embecta UK have announced they have signed a partnership agreement under which embecta sales representatives will promote PolyPhotonix’s Noctura 400 Sleep Mask to healthcare professionals within the UK and Ireland, effective immediately.
Both companies are dedicated to improving the lives of people with diabetes. Having spun off from BD (Becton, Dickinson and Company) in April of last year, embecta is one of the world’s largest pure-play diabetes companies and, with a nearly 100-year history of leadership in insulin delivery, is well established across the UK market. PolyPhotonix has developed the Noctura 400 Sleep Mask a home based, non-invasive monitored treatment of diabetic retinopathy (1-6) a condition associated with diabetic mellitus that can lead to blindness*.
“We are very excited about the partnership with embecta UK,” said Richard Kirk, CEO of PolyPhotonix. “Working with such an experienced team means that we can bring this innovative treatment to many more patients faster, potentially reducing the rate of disease progression and associated loss of visual acuity. For the NHS, treating people with diabetic retinopathy with the Noctura 400 sleep mask represents a cost-effective alternative to existing treatments. At a time when our healthcare budgets are already stretched, bringing Noctura 400 to existing care pathways makes sound financial sense, freeing up hospital appointments for those in greater need of hospital-based care.”
“The agreement to promote Noctura 400 to healthcare professionals not only enables us to expand our offerings of diabetes care solutions to the NHS, but it does so within an innovative new category,” said Sinéad North, Country General Manager for embecta UK.
